A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease.
Carpenter PA, Appelbaum FR, Corey L, Deeg HJ, Doney K, Gooley T, Krueger J, Martin P, Pavlovic S, Sanders J, Slattery J, Levitt D, Storb R, Woolfrey A, Anasetti C.
Carpenter PA, et al. Among authors: deeg hj.
Blood. 2002 Apr 15;99(8):2712-9. doi: 10.1182/blood.v99.8.2712.
Blood. 2002.
PMID: 11929757
Free article.
Clinical Trial.